The major pathways of elimination of many drugs are the kidneys (urine) and the liver where they are conjugated (e.g. with glucuronic acid). Drug metabolites predominantly can be detected in urine, such as a result of heroin, morphine, codeine, or poppy seed intake. For example, an Athendia false negative free test can detect the concentration of Opiates in urine exceeding 300ng/mL.
Athendia drug abuse rapid test: is a rapid screening test for the qualitative detection of different drugs in human urine at specified cut-off levels. Athendia rapid tests are for professional use only and for in vitro diagnostic use only.
Athendia Drug Abuse Rapid Test intended use:
Drug Abuse Rapid Test is an Immuno-chromatographic assay for the qualitative determination of the presence of drugs (e.g. Morphine) in the human urine sample. This assay provides only a preliminary analytical test result or screening test. Gas Chromatography/Mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to each drug-specific test result, particularly when preliminary positive results are indicated. For adulterations, some test results are false negative and Athendia Rapid tests for drug abuse are False Negative Free Tests (FNFT).
Athendia False Negative Free Tests (AFNFT): are competitive immunoassays that use a chromatographic absorbent device to screen for the presence of drug metabolites in urine. In this device, drugs in a urine sample compete with a limited number of drug monoclonal antibody (mouse) conjugate binding sites. When the test is activated, the urine is absorbed into the test by capillary action, mixed with the drug monoclonal antibody conjugate, and flows across a pre-coated membrane. If the drug level in the urine sample is below the test’s detection limit, the drug monoclonal antibody conjugate binds to the drug-protein conjugate immobilized in the Test Region (T) of the test, producing a colored Test line in the Test Region (T). This indicates a negative test result, regardless of the intensity of the line. If the drug level in the sample is at or above the test’s detection limit, the free drug in the sample binds to the drug monoclonal antibody conjugate, preventing the drug monoclonal antibody conjugate from binding to the drug-protein conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct colored band in the test region, indicating a preliminary positive result. A colored line will appear at the Control Region (C) of the Test to serve as a procedure control, indicating that the test was performed properly.
Athendia FNFT Interpretation of Results:
Preliminary positive (+): Only one colored band appears, in the control region (C). No colored band appears in the test region (T).
True Negative (-): Two colored bands appear on the membrane. One band appears in the control region (C) and another band appears in the test region (T). No band in interference region (I).
False Negative (+): One colored band appears on the membrane. One band appears in the control region (C) No band appears in the test region (T) and No band in the interference region (I). It shows adulteration.
Invalid: Control band fails to appear. Results from any test that has not produced a control band at the specified read time must be discarded. Please review the procedure and repeat it with a new test. If the problem persists, discontinue using the kit immediately and contact your local distributor.
- Athendia Ltd 270 George Street N, Third Floor, Peterborough, Ontario, Canada, K9J 3H1 Phone: +1 705 7617904